Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atopis
- Development stage
- Unknown
- Lead developer
- Decima Health
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
**Atopis** is a branded topical natural skin-care product range developed by Decima Health, with an eczema-focused cream historically marketed as Atopis Eczema Therapy Cream. Its proprietary key ingredient, Myriphytase, is a multi-component fermented natural preparation incorporating plant-, bacterial-, and bee-derived materials rather than an INN-defined single active pharmaceutical ingredient. The developer describes Myriphytase-containing creams as reducing inflammatory interleukin-6 signaling in human cells and providing anti-inflammatory, antimicrobial, moisturizing, emollient, and skin-barrier-supportive effects; these claims are company descriptions and are not a validated target-specific pharmacologic mechanism. Atopis has been marketed for dry, itchy, eczema-prone skin and the broader brand now includes distinct products for other skin conditions. ([atopis.co.nz](https://atopis.co.nz/the-scientific-invention-inside-atopis-natural-skin-care/))
- Brand names
- AtopisMed
- Other names
- Bionona Atopis Med
02
Targets
IL-6 (Interleukin 6)
Beyond the preview
Go deeper on Atopis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atopis.